Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples